Clinical Trial Update: Efficacy and Safety of TRC041266 in Patients With Heart Failure, LVEF ≥40%, Diastolic Dysfunction and Type 2 Diabetes Mellitus [Phase 3]

View source ↗

Summary

Phase 3 trial of TRC041266 in chronic stable heart failure with diastolic dysfunction and type 2 diabetes mellitus was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stable Heart Failure

Drugs mentioned

• TRC041266

Snippet

Sponsor: Torrent Pharmaceuticals Limited | Conditions: Chronic Stable Heart Failure | Phase 3 | Status: WITHDRAWN